Searchable abstracts of presentations at key conferences on calcified tissues

ba0002p105 | (1) | ICCBH2013

Bisphosphonate treatment in non-ambulatory patients with spastic quadriplegic cerebral palsy and other neuromuscular disorders: effectiveness of pamidronate vs zoledronic acid

Bowden Sasigarn , Jessup Ashley , Wang Wei , Mahan John

Objectives: To examine the bone mineral density (BMD) response to i.v. pamidronate (Group 1) vs i.v. zoledronic acid (Group 2) in non-ambulatory children and young adults with severe cerebral palsy or other neuromuscular disorders.Methods: A total of 50 non-ambulatory children and young adults, (mean age 11.3 years, range 2.1–32) with low BMD and/or history of fractures were retrospectively studied. Thirty-nine patients (30 spastic quadriplegic cere...

ba0004p27 | (1) | ICCBH2015

Bone mineral density and clinical outcome after intravenous bisphosphonate discontinuation in children with osteogenesis imperfecta

Bowden Sasigarn , Heksch Ryan , Hickey Scott , Mahan John

Objectives: i) To evaluate the bone mineral density (BMD), and clinical outcomes of intravenous bisphosphonate treatment (IVT) and after treatment discontinuation in children with osteogenesis imperfecta (OI). ii) To compare the clinical outcome of those who discontinued IVT and those who had progressed from IVT to maintenance oral bisphosphonate therapy.Methods: A retrospective study was conducted on 28 children with OI who had discontinued IVT (21 pami...

ba0004p39 | (1) | ICCBH2015

Fracture and bone mineral density outcomes after bisphosphonate discontinuation in children with osteogenesis imperfecta treated with zoledronic acid compared to pamidronate

Heksch Ryan , Bowden Sasigarn , Hickey Scott , Mahan John

Objectives: Cyclical intravenous pamidronate (PAM) and zoledronic acid (ZOL) increases bone mineral density (BMD) and reduces fractures in children with osteogenesis imperfecta (OI). The aims of this study were to evaluate fracture and BMD outcomes after treatment discontinuation in children with OI treated with ZOL compared to PAM.Methods: 21 patients (mean age 5.1±3.8 years) received PAM (1 mg/kg per day x 3 days q 3 months for the first year). Se...

ba0004is11biog | (1) (1) | ICCBH2015

Recent advances in limb lengthening and deformity correction

Herzenberg John

Biographical DetailsDr John Herzenberg graduated from Boston University Medical School and trained at Duke University for Orthopaedics and Toronto Sick Kids for Pediatric Orthopaedics. He specializes in the diagnosis and treatment of adult and pediatric patients with congenital abnormalities, joint contractures, neuromuscular disorders, non-unions, malunions, deformity, and bone defects. ...

ba0001d1.1 | (1) | ECTS2013

For the motion (ECTS)

Campbell John

The incidence of hip fractures is declining in later cohorts of older people but, if the cohort effect is controlled for, the period effect shows a steady increase in incidence. This is almost certainly because we are seeing the survival of an increasingly frail group of older people with comorbidities. The great majority of hip fractures result from falls. There is strong research evidence that falls can be prevented. Proven strength and balance programmes reduce the rate of ...

ba0003d1.1 | (1) | ECTS2014

Debate: there are more benefits than risks associated with HRT in postmenopausal women: for the motion

Stevenson John

Hormone replacement therapy (HRT) comprises estrogen, with or without progestogen addition, given to postmenopausal women. HRT is by far the most effective treatment for the relief of menopausal symptoms such as vasomotor and genito-urinary symptoms. It is as effective as alternative treatments for the prevention of postmenopausal osteoporosis. It increases bone mass, reduces bone turnover, and reduces fracture risk at all the important skeletal sites. It has a beneficial effe...

ba0004is11 | (1) (1) | ICCBH2015

Recent advances in limb lengthening and deformity correction

Herzenberg John

External fixation has been the gold standard for patients who require bone lengthening. This method is accurate and reliable, but can result in significant scarring, superficial infection, and pain. Additionally, the daily care of pin sites, unsightly appearance of the device, and reduced function can be emotionally taxing for both the patient and caregivers. An internal device that lengthens through rotational movement was developed to address some of these issues (ISKD). Alt...

ba0001pp227 | Cell biology: osteoclasts and bone resorption | ECTS2013

RANKL immobilized on β-TCP induces and maintains osteoclast formation

Choy John , Hofstetter Wilhelm , Klenke Frank M

β-tricalcium phosphate (β-TCP) biomaterials have been approved for the repair of osseous defects. However, in large defects, the substitution of biomaterial by authentic bone is inadequate to provide sufficient long-term mechanical stability. We aimed to develop composites of β-TCP ceramics and receptor activator of nuclear factor κ-B ligand (RANKL) to enhance the formation of osteoclasts thereby stimulating material resorption. RANKL was immobilized on &#9...

ba0003pp73 | Bone development/growth and fracture repair | ECTS2014

S.C. injection of recombinant human parathyroid hormone rhPTH(1--84) in thigh provides a more prolonged pharmacokinetic profile and a greater calcemic response when compared with injection in abdomen

Fox John , Garceau Roger , Lagast Hjalmar

Recombinant human parathyroid hormone (rhPTH) (1–84) is currently being developed as PTH replacement therapy for patients with hypoparathyroidism. Because rhPTH(1–84) is administered subcutaneously, we compared the pharmacokinetic profile of PTH(1–84) and the calcemic response following S.C. rhPTH(1–84) injection in thigh and abdomen.In this phase 1, open-label, three-way crossover study, healthy postmenopausal women received three ra...